Nektar says Phase 2b REZOLVE-AA trial posts new 6-month off-treatment data

Company says the update covers rezpegaldesleukin data in severe alopecia areata and will be presented at EADV 2026 in Vienna. Nektar also plans an Oct. 1, 2026 investor webcast on the off-treatment results.